|
A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2). |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; Sillajen; Sirtex Medical |
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; MSD; Sirtex Medical |
Speakers' Bureau - Bayer Schering Pharma; Lilly |
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical |
|
|
Honoraria - Ajinomoto; Bayer; Eisai; MSD |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Chugai Pharma; Kowa; MSD; Taiho Pharmaceutical |
Research Funding - Abbvie; Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; MSD; Otsuka; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck; Novartis; Pfizer |
Research Funding - Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
Consulting or Advisory Role - Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celsion; Eisai; Incyte; Lilly |
Research Funding - Bayer Schering Pharma (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst) |
Travel, Accommodations, Expenses - Bayer |